Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Vulvovaginal candidiasis

Essential points for quick revision.

Saved on this device
!
Symptoms outside uncomplicated vulvovaginal candidiasis

Fever, pelvic or abdominal pain, haemodynamic instability, peritonism, rapidly progressive vulval inflammation, urinary retention or pain and bleeding in pregnancy requires assessment for another acute diagnosis.

Action: Record observations and pregnancy status, examine the abdomen, pelvis and vulva as clinically indicated, and arrange same-day acute or specialist care. Repeated antifungal treatment must not delay evaluation of upper-genital-tract disease, ectopic pregnancy, invasive infection or a severe vulval disorder.

Synopsis

Diagnose inflammatory Candida vulvovaginitis rather than treating a culture result, manage pregnancy safely, and investigate repeated symptoms before committing a patient to recurrent-disease suppression.

  • VVC is an inflammatory syndrome: itch, soreness, burning, erythema, oedema or fissuring matters more than whether discharge looks curdy.
  • No symptom or discharge appearance is diagnostic; inspect persistent or atypical disease and consider dermatitis, dermatosis, herpes, vulvodynia, trichomoniasis and cervical infection.
  • Use microscopy to support symptomatic infection, and interpret culture with the examination because Candida growth without symptoms is colonisation.

Key red flags

Fever, lower abdominal pain, cervical excitation or adnexal tenderness is not explained by uncomplicated VVC and requires a pelvic-infection and emergency differential.

Collapse, shoulder-tip pain, bleeding or significant abdominal pain when pregnancy is possible requires urgent ectopic-pregnancy assessment.

Rapidly spreading erythema, tissue necrosis, marked oedema, ulceration or inability to pass urine demands examination for severe infection or another vulval process.

Postcoital, intermenstrual or postmenopausal bleeding needs cervical and cancer-focused assessment rather than attribution to thrush.

Severe or refractory inflammation with poorly controlled diabetes or major immunosuppression requires culture, species identification and specialist-directed management.

Investigation priorities

01
Microscopy during symptomsFirst step

Link a current inflammatory episode to budding yeast or pseudohyphae before treatment obscures the finding.

Management branches

ACUTETreat a supported acute episode

A stable adult has a first or occasional episode with a compatible inflammatory pattern.

  1. Ask about itch, soreness, external dysuria, odour, pelvic symptoms, bleeding, pregnancy possibility, recent antibiotics, diabetes risk and products already applied.
  2. Examine and obtain microscopy when symptoms are severe, atypical, persistent or diagnostically uncertain; do not let discharge colour substitute for syndrome recognition.

Key medicines

Clotrimazole vaginal pessaryInsert 500 mg intravaginally once for uncomplicated vulvovaginal candidiasis; use a longer topical azole course in pregnancy.Follow the formulation instructions, avoid forceful applicator use in pregnancy and examine persistent symptoms before another empiric course.
FluconazoleTake 150 mg orally as a single dose for suitable uncomplicated vulvovaginal candidiasis.Avoid in pregnancy; review hepatic disease, QT risk and interacting medicines, and confirm recurrent disease before prolonged off-label suppression.
Open full textbook Answer 2 questions
Sources and review status5 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom